<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002528</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000078383</org_study_id>
    <secondary_id>IBCSG-10-93</secondary_id>
    <secondary_id>EU-93013</secondary_id>
    <secondary_id>NCI-F93-0008</secondary_id>
    <nct_id>NCT00002528</nct_id>
  </id_info>
  <brief_title>Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer</brief_title>
  <acronym>10-93</acronym>
  <official_title>Surgical Therapy With or Without Axillary Node Clearance for Breast Cancer in the Elderly Who Receive Adjuvant Therapy With Tamoxifen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Removing axillary lymph nodes may be effective in stopping the spread of breast
      cancer cells. It is not yet known if surgery to remove breast cancer is more effective with
      or without lymph node removal.

      PURPOSE: Randomized phase III trial to compare the effectiveness of breast surgery with or
      without removal of axillary lymph nodes in treating women who have stage I or stage IIA
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare local and systemic disease-free survival, ipsilateral axillary relapse,
           occurrence of postmastectomy syndrome, and overall survival of elderly women with
           clinically operable stage I or IIA breast cancer who subsequently receive adjuvant
           tamoxifen after treatment with breast surgery with or without axillary node dissection.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the quality of life in patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      whether they received prior primary surgery (yes vs no) and participating center.

        -  Arm I: Patients undergo mastectomy, lumpectomy, or quadrantectomy with axillary
           clearance. Patients then receive oral tamoxifen for 5 years. Patients may also undergo
           sentinel node biopsy.

        -  Arm II: Patients undergo surgery as in arm I without axillary clearance. Patients then
           receive oral tamoxifen for 5 years.

      Patients in both arms who undergo breast-conserving surgery may receive optional radiotherapy
      for 5-6 weeks to the remaining breast tissue, chest, and lung. Upon recurrence in the
      conserved breast, patients undergo total mastectomy; those in arm II who experience
      ipsilateral axillary recurrence undergo surgical excision. Adjuvant tamoxifen and follow up
      are continued.

      Quality of life is assessed.

      Patients are followed every 3 months for 1 year, every 6 months while receiving tamoxifen,
      and then annually thereafter.

      PROJECTED ACCRUAL: A total of 1,020 patients will be accrued for this study within
      approximately 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1993</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Time from randomization to recurrence, metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Time from randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Side effects of treatment, especially surgery-related events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Quality of life will be assessed by standard International Breast Cancer Study Group instruments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">473</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery w/ axillary clearance, tamox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery w/o axillary clearance, tamox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.</description>
    <arm_group_label>Surgery w/ axillary clearance, tamox</arm_group_label>
    <arm_group_label>Surgery w/o axillary clearance, tamox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).</description>
    <arm_group_label>Surgery w/ axillary clearance, tamox</arm_group_label>
    <arm_group_label>Surgery w/o axillary clearance, tamox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.</description>
    <arm_group_label>Surgery w/ axillary clearance, tamox</arm_group_label>
    <arm_group_label>Surgery w/o axillary clearance, tamox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary clearance</intervention_name>
    <description>Axillary node dissection.</description>
    <arm_group_label>Surgery w/ axillary clearance, tamox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage I or IIA breast carcinoma that is
             considered operable

          -  No prior axillary clearance or biopsy

          -  Complete excisional biopsy of primary tumor without axillary clearance or biopsy
             allowed

          -  Suspicious manifestations of metastatic disease (e.g., hot spots on bone scan or
             skeletal pain of unknown cause) must be proven benign

          -  No bilateral breast cancer (any mass in contralateral breast must be proven benign by
             biopsy)

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  60 and over

        Sex:

          -  Female

        Menopausal status

          -  Postmenopausal

        Performance status:

          -  Not specified

        Hematopoietic:

          -  WBC greater than 4,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.1 mg/dL

          -  AST less than 60 U/L

        Renal:

          -  Creatinine less than 1.3 mg/dL

        Cardiovascular:

          -  Normal cardiac function

          -  No history of congestive heart failure

        Other:

          -  No nonmalignant systemic disease that would preclude protocol therapy or prolonged
             follow-up

          -  No psychiatric or addictive disorder that would preclude protocol therapy or informed
             consent

          -  No other prior or concurrent malignancy except nonmelanomatous skin cancer or
             adequately treated carcinoma in situ of the cervix

          -  Geographically accessible for follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy for breast cancer

        Chemotherapy:

          -  No prior chemotherapy for breast cancer

        Endocrine therapy:

          -  No prior endocrine therapy for breast cancer

        Radiotherapy:

          -  No prior radiotherapy for breast cancer

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Crivellari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro di Riferimento Oncologico - Aviano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital, Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anti-Cancer Council of Victoria, Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital, Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero-Gorizia</name>
      <address>
        <city>Gorizia</city>
        <zip>34170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Adventist Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>5</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital, Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg (Goteborg)</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Th√ºrlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5.</citation>
    <PMID>18458044</PMID>
  </reference>
  <results_reference>
    <citation>International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20;24(3):337-44. Epub 2005 Dec 12.</citation>
    <PMID>16344321</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

